Global Human Insulin Market- Industry Analysis and Forecast (2020-2027) – By Application, Type, Distribution Channel, Brand, Drug Delivery Devices and Region.

Global Human Insulin Market- Industry Analysis and Forecast (2020-2027) – By Application, Type, Distribution Channel, Brand, Drug Delivery Devices and Region.

Market Scenario

The Global Human Insulin Market was valued at USD 28.62 Bn in 2019 is estimated to reach US$ 32.17 Bn in 2027, growing at a CAGR of 4.93% during the forecasted period.   Market Definition: Human Insulin is a short-acting insulin that lowers the glucose level in the body made by beta cells in the pancreas and used for hyperglycemia treatment caused by Type 1 and Type 2 Diabetes. Human insulin is manufactured in laboratories by insulin protein with E. coli bacteria and produced by recombinant DNA technology produce. Diabetes Mellitus (DM) is the chronic condition and occurs due to inadequate secretion of insulin in which blood sugar level is high. The report study has analyzed revenue impact of covid-19 pandemic on the sales revenue of market leaders, market followers and disrupters in the report and same is reflected in our analysis. Market Dynamics: The report estimates the growth rate of Human Insulin Market and offers in-depth insights on market dynamics, drivers, restraints, challenges and threats till 2027. The complete information is based on the latest industry news, opportunities, and trends. Diabetes is the most prominent health disease and is increasing disgracefully with increasing population and is one of the most common recurrence health problems occurs due to high glucose level in blood. Over time, it often results to complication like hyperglycemic, diabetic ketoacidosis, heart attack, and kidney failure leading to premature death, In order to eradicate these health issue human insulin market is projected to increase considerably. According to the research about 100 Mn. people requires insulin of which 10-25% of people suffering from Type 2 diabetes. According, to the International Diabetes Federation, in 2016, around 159 Mn. people suffers from diabetes currently it is estimated to be 425 Mn. and it is predictable to grow to 283 Mn. by 2045. Furthermore, increasing awareness and investment in R&D has led to an increase in diagnosis rate and is estimated to propel the market over the forecast. However, over 90 years, insulin has been used in diabetes treatment, more than half who need insulin today still cannot access to afford it. Global Human Insulin Market: Trends and Opportunities • With the growing need for human insulin, this market consist various opportunities such as application of protocols against needle stick injuries, needle anxiety, and rising awareness correlated to the threat related to the transmission of the bloodborne pathogen. • Biocon an oral prandial insulin tablet, is developing Tregopil Insulin, use for the treatment in diabetes mellitus of type-1 and type-2. • Oramed Pharmaceuticals Inc focusing in the development of first oral insulin product providing a more effective, convenient, as well as a safer method for delivering insulin therapy. Recent industry developments: • In August 2018, Ypsomed AG came in partnership with JRDF, the prominent global organization funding type I diabetes research, as a part of JDRF's Open-Protocol Automated Insulin Delivery (AID) Systems Initiative., JRDF also claim to provide financial assets to help Ypsomed AG to speed up the development of the next generation. • Furthermore, the World Health Organization (WHO) for the prevention and control of non-communicable diseases (NCDs) developed the action plan which delivered a roadmap for the execution of policies and programs at the national and regional level, thus driving the human insulin market growth in the region. Global Human Insulin Market,Market Segmentation: The report covers the brief analytical segments of the Human Insulin Market thereby providing a wider view at the macro as well as micro levels. In terms of application, Type II diabetes is expected to have the largest market progressing at a CAGR of 9.1% with a revenue of $35.1 Bn during the forecast period. This is mainly attributed because of the changing lifestyle. The rate of recurrence rate of Type 2 diabetes has multiplied in comparison to past 40 years ago. Thus, the aggregate incidence of diabetes and diabetes obesity in the world is likely to raise demand for insulin, which may drive the global market for insulin therapeutics. Based on product type, Analogue insulin accounting for 79.5% shares and highest revenue and is expected to grow at the fastest rate during the forecast. Analogue insulin is rapidly growing because of increasing efficacy and response rate and other advantages provide as compared to traditional and high demand over five years, Analogue insulin is further subdivided into Long Acting insulin, short-acting insulin, Fast Acting Insulin and Premixed Insulin. Furthermore, current development and product launch such as Eli Lilly launched Lispro rapidly acting analogue insulin which shall be available during the forecast around the world and U.S in half of the price making it more accessible for diabetes patients and expected to propel the market. Global Human Insulin Market, Regional analysis Geographically, North America dominated the growth of Human Insulin Market with the largest share of 43% and is expected to continue its dominance to reach US$ XX Bn by 2027, with a CAGR of XX% during the forecast period. According to statistics in U.S approximately 30.3 Mn population(9.4%) suffering from diabetes off which 23.1 Mn were diagnosed and remaining were undiagnosed, diabetic is the 7 leading causing of death in US and U.S claims to spends annually highest amount 245 Bn dollars in treatment for insulin dependent patients which in turn, raise the market growth. The growth is driven by well-developed healthcare infrastructure with, existing manufacturers and the increasing pediatric population suffering from type 1 diabetes across the region. Moreover, increasing investment in R&D with technology advancement and increasing health care expenditure, increasing the occurrence of diabetes, and rise in the geriatric population. Currently, about 25% of adults over 60 years suffered from diabetes. Furthermore, Europe is the second largest region and 60 Mn people suffer from diabetes in which 10.3% is men and 9.6% is women and is increasing mainly due to obesity, unhealthy diet and, overweight. Asia pacific is anticipated to grow at highest CAGR during the forecast in which china is with highest number around 116 Mn after which india with $1.95 Billion in 2019 and is Projected to Grow at a CAGR of 16.7% During 2019-2027. Competitive Analysis: The competitive landscape section in the Human Insulin Market highly fragmented and offers various strategies such as mergers, new product launches and acquisitions, joint ventures, and other crucial aspects rise the competitive market. For instance, Eli Lilly alliance with Boehringer Ingelheim for developing and commercializing Insulin Glargine. • In august 2018, Novo Nordisk purchases ziylo overall share with this acquisition Novo Nordisk acquired all the rights to ziylo in developing glucose-responsive insulin (GRI) leading to more effective and safe insulin therapy. • In April 2015, Biocon proclaimed that its Insulin Glargine is approved by COFEPRIS together with its partner (PiSA) to reinforce its position in Mexico. The objective of the report is to present a comprehensive analysis of the Global Human Insulin Market including all the stakeholders of the industry. The past and current status of the industry with forecasted market size and trends are presented in the report with the analysis of complicated data in simple language. The report covers all the aspects of the industry with a dedicated study of key players that includes market leaders, followers, and new entrants. PORTER, SVOR, PESTEL analysis with the potential impact of micro-economic factors of the market has been presented in the report. External as well as internal factors that are supposed to affect the business positively or negatively have been analyzed, which will give a clear futuristic view of the industry to the decision-makers. The report also helps in understanding Global Human Insulin Market dynamics, structure by analyzing the market segments and projects the Global Human Insulin Market size. Clear representation of competitive analysis of key players By Type, price, financial position, Product portfolio, growth strategies, and regional presence in the Global Human Insulin Market make the report investor’s guide.

Scope of the Global Human Insulin Market:

Global Human Insulin Market, By Application

• Diabetes Type 1 • Diabetes Type 2

Global Human Insulin Market, By Type

• Analogue Insulin     Long-Acting     Fast-Acting     Premix • Traditional human Insulin    Long-Acting    Short-Acting    Fast-Acting    Premix

Global Human Insulin Market, By Distribution Channel

• Retail Pharmacies • Hospital Pharmacies • Online Pharmacies

Global Human Insulin Market, By Brand

• Lantus • Apidra • Levemir • NovoRapid/ NovoLog • Novomix • Humalog • Others

Global Human Insulin Market, By Drug Delivery Devices

• Pens • Pen Needles • Syringes • Pumps

Global Human Insulin Market, By Region

• North America • Europe • Asia Pacific • Middle East and Africa • Latin America

Global Human Insulin Market, key Players

• B. Braun Melsungen AG • ALBIREO PHARMA, INC • BECTON, DICKINSON AND COMPANY • BIOCON LIMITED • Sanofi Aventis • WOCKHARDT LIMITED • JULPHAR • YPSOMED HOLDING AG • ELI LILLY AND COMPANY • NOVO Nordisk A/S • ADOCIA • Tonghua Dongbao Pharmaceutical Co., LTD • GSK • Gulf Pharmaceutical Industries • Medtronic PLC • Oramed Pharmaceuticals, Inc • SemBioSys Genetics • Pfizer, Inc. • Merck & Co., Inc.

Table of Contents

Global Human Insulin Market 1. Preface 1.1. Report Scope and Market Segmentation 1.2. Research Highlights 1.3. Research Objectives 2. Assumptions and Research Methodology 2.1. Report Assumptions 2.2. Abbreviations 2.3. Research Methodology 2.3.1. Secondary Research 2.3.1.1. Secondary data 2.3.1.2. Secondary Sources 2.3.2. Primary Research 2.3.2.1. Data from Primary Sources 2.3.2.2. Breakdown of Primary Sources 3. Executive Summary: Global Human Insulin Market size, by Market Value (US$ Bn) 4. Market Overview 4.1. Introduction 4.2. Market Indicator 4.2.1. Drivers 4.2.2. Restraints 4.2.3. Opportunities 4.2.4. Challenges 4.3. Porter’s Analysis 4.4. Value Chain Analysis 4.5. Market Risk Analysis 4.6. SWOT Analysis 4.7. Industry Trends and Emerging Technologies 5. Supply Side and Demand Side Indicators 6. Global Human Insulin Market Analysis and Forecast 6.1. Human Insulin Market Size & Y-o-Y Growth Analysis 6.1.1. North America 6.1.2. Europe 6.1.3. Asia Pacific 6.1.4. Middle East & Africa 6.1.5. South America 7. Global Human Insulin Market Analysis and Forecast, By Application 7.1. Introduction and Definition 7.2. Key Findings 7.3. Human Insulin Market Value Share Analysis, By Application 7.4. Human Insulin Market Size (US$ Bn) Forecast, By Application 7.5. Human Insulin Market Analysis, By Application 7.6. Human Insulin Market Attractiveness Analysis, By Application 8. Global Human Insulin Market Analysis and Forecast, By Type 8.1. Introduction and Definition 8.2. Key Findings 8.3. Human Insulin Market Value Share Analysis, By Type 8.4. Human Insulin Market Size (US$ Bn) Forecast, By Type 8.5. Human Insulin Market Analysis, By Type 8.6. Human Insulin Market Attractiveness Analysis, By Type 9. Global Human Insulin Market Analysis and Forecast, By Distribution Channel 9.1. Introduction and Definition 9.2. Key Findings 9.3. Human Insulin Market Value Share Analysis, By Distribution Channel 9.4. Human Insulin Market Size (US$ Bn) Forecast, By Distribution Channel 9.5. Human Insulin Market Analysis, By Distribution Channel 9.6. Human Insulin Market Attractiveness Analysis, By Distribution Channel 10. Global Human Insulin Market Analysis and Forecast, By brand 10.1. Introduction and Definition 10.2. Key Findings 10.3. Human Insulin Market Value Share Analysis, By brand 10.4. Human Insulin Market Size (US$ Bn) Forecast, By brand 10.5. Human Insulin Market Analysis By brand 10.6. Human Insulin Market Attractiveness Analysis, By brand 11. Global Human Insulin Market Analysis and Forecast, By Drug Delivery Devices 11.1. Introduction and Definition 11.2. Key Findings 11.3. Human Insulin Market Value Share Analysis, By Drug Delivery Devices 11.4. Human Insulin Market Size (US$ Bn) Forecast, By Drug Delivery Devices 11.5. Human Insulin Market Analysis By Drug Delivery Devices 11.6. Human Insulin Market Attractiveness Analysis, By Drug Delivery Devices 12. Global Human Insulin Market Analysis, by Region 12.1. Human Insulin Market Value Share Analysis, by Region 12.2. Human Insulin Market Size (US$ Bn) Forecast, by Region 12.3. Human Insulin Market Attractiveness Analysis, by Region 13. North America Human Insulin Market Analysis 13.1. Key Findings 13.2. North America Human Insulin Market Overview 13.3. North America Human Insulin Market Value Share Analysis, By Application 13.4. North America Human Insulin Market Forecast, By Application 13.4.1. Diabetes Type 1 13.4.2. Diabetes Type 2 13.5. North America Human Insulin Market Value Share Analysis, By Type 13.6. North America Human Insulin Market Forecast, By Type 13.6.1. Analogue Insulin 13.6.1.1. Long-Acting 13.6.1.2. Fast-Acting 13.6.1.3. Premix 13.6.2. Traditional human Insulin 13.6.2.1. Long-Acting 13.6.2.2. Short-Acting 13.6.2.3. Fast-Acting 13.6.2.4. Premix 13.7. North America Human Insulin Market Value Share Analysis, By Distribution Channel 13.8. North America Human Insulin Market Forecast, By Distribution Channel 13.8.1. Retail Pharmacies 13.8.2. Hospital Pharmacies 13.8.3. Online Pharmacies 13.9. North America Human Insulin Market Value Share Analysis, By brand 13.10. North America Human Insulin Market Forecast, By brand 13.10.1. Lantus 13.10.2. Apidra 13.10.3. Levemir 13.10.4. NovoRapid/ NovoLog 13.10.5. Novomix 13.10.6. Humalog 13.10.7. Others 13.11. North America Human Insulin Market Value Share Analysis, By Drug Delivery Devices 13.12. North America Human Insulin Market Forecast, By Drug Delivery Devices 13.12.1. Pens 13.12.2. Pen Needles 13.12.3. Syringes 13.12.4. Pumps 13.13. North America Human Insulin Market Value Share Analysis, by Country 13.14. North America Human Insulin Market Forecast, by Country 13.14.1. U.S. 13.14.2. Canada 13.15. North America Human Insulin Market Analysis, by Country 13.16. U.S. Human Insulin Market Forecast, By Application 13.16.1. Diabetes Type 1 13.16.2. Diabetes Type 2 13.17. U.S. Human Insulin Market Forecast, By Type 13.17.1. Analogue Insulin 13.17.1.1. Long-Acting 13.17.1.2. Fast-Acting 13.17.1.3. Premix 13.17.2. Traditional human Insulin 13.17.2.1. Long-Acting 13.17.2.2. Short-Acting 13.17.2.3. Fast-Acting 13.17.2.4. Premix 13.18. U.S. Human Insulin Market Forecast, By Distribution Channel 13.18.1. Retail Pharmacies 13.18.2. Hospital Pharmacies 13.18.3. Online Pharmacies 13.19. U.S. Human Insulin Market Forecast, By brand 13.19.1. Lantus 13.19.2. Apidra 13.19.3. Levemir 13.19.4. NovoRapid/ NovoLog 13.19.5. Novomix 13.19.6. Humalog 13.19.7. Others 13.20. U.S. Human Insulin Market Forecast, By Drug Delivery Devices 13.20.1. Pens 13.20.2. Pen Needles 13.20.3. Syringes 13.20.4. Pumps 13.21. Canada Human Insulin Market Forecast, By Application 13.21.1. Diabetes Type 1 13.21.2. Diabetes Type 2 13.22. Canada Human Insulin Market Forecast, By Type 13.22.1. Analogue Insulin 13.22.1.1. Long-Acting 13.22.1.2. Fast-Acting 13.22.1.3. Premix 13.22.2. Traditional human Insulin 13.22.2.1. Long-Acting 13.22.2.2. Short-Acting 13.22.2.3. Fast-Acting 13.22.2.4. Premix 13.23. Canada Human Insulin Market Forecast, By Distribution Channel 13.23.1. Retail Pharmacies 13.23.2. Hospital Pharmacies 13.23.3. Online Pharmacies 13.24. Canada Transplantation Market Forecast, By brand 13.24.1. Lantus 13.24.2. Apidra 13.24.3. Levemir 13.24.4. NovoRapid/ NovoLog 13.24.5. Novomix 13.24.6. Humalog 13.24.7. Others 13.25. Canada Transplantation Market Forecast, By Drug Delivery Devices 13.25.1. Pens 13.25.2. Pen Needles 13.25.3. Syringes 13.25.4. Pumps 13.26. North America Human Insulin Market Attractiveness Analysis 13.26.1. By Application 13.26.2. By Type 13.26.3. By Distribution Channel 13.26.4. By Brand 13.26.5. By Drug Delivery Devices 13.27. PEST Analysis 13.28. Key Trends 13.29. Key Developments 14. Europe Human Insulin Market Analysis 14.1. Key Findings 14.2. Europe Human Insulin Market Overview 14.3. Europe Human Insulin Market Value Share Analysis, By Application 14.4. Europe Human Insulin Market Forecast, By Application 14.4.1. Diabetes Type 1 14.4.2. Diabetes Type 2 14.5. Europe Human Insulin Market Value Share Analysis, By Type 14.6. Europe Human Insulin Market Forecast, By Type 14.6.1. Analogue Insulin 14.6.1.1. Long-Acting 14.6.1.2. Fast-Acting 14.6.1.3. Premix 14.6.2. Traditional human Insulin 14.6.2.1. Long-Acting 14.6.2.2. Short-Acting 14.6.2.3. Fast-Acting 14.6.2.4. Premix 14.7. Europe Human Insulin Market Value Share Analysis, By Distribution Channel 14.8. Europe Human Insulin Market Forecast, By Distribution Channel 14.8.1. Retail Pharmacies 14.8.2. Hospital Pharmacies 14.8.3. Online Pharmacies 14.9. Europe Human Insulin Market Value Share Analysis, By brand 14.10. Europe Human Insulin Market Forecast, By brand 14.10.1. Lantus 14.10.2. Apidra 14.10.3. Levemir 14.10.4. NovoRapid/ NovoLog 14.10.5. Novomix 14.10.6. Humalog 14.10.7. Others 14.11. Europe Human Insulin Market Value Share Analysis, By Drug Delivery Devices 14.12. Europe Human Insulin Market Forecast, By Drug Delivery Devices 14.12.1. Pens 14.12.2. Pen Needles 14.12.3. Syringes 14.12.4. Pumps 14.13. Europe Human Insulin Market Value Share Analysis, by Country 14.14. Europe Human Insulin Market Forecast, by Country 14.14.1. Germany 14.14.2. U.K. 14.14.3. France 14.14.4. Italy 14.14.5. Spain 14.14.6. Rest of Europe 14.15. Europe Human Insulin Market Analysis, by Country 14.16. Germany Human Insulin Market Forecast, By Application 14.16.1. Diabetes Type 1 14.16.2. Diabetes Type 2 14.17. Germany Human Insulin Market Forecast, By Type 14.17.1. Analogue Insulin 14.17.1.1. Long-Acting 14.17.1.2. Fast-Acting 14.17.1.3. Premix 14.17.2. Traditional human Insulin 14.17.2.1. Long-Acting 14.17.2.2. Short-Acting 14.17.2.3. Fast-Acting 14.17.2.4. Premix 14.18. Germany Human Insulin Market Forecast, By Distribution Channel 14.18.1. Retail Pharmacies 14.18.2. Hospital Pharmacies 14.18.3. Online Pharmacies 14.19. Germany Human Insulin Market Forecast, By brand 14.19.1. Lantus 14.19.2. Apidra 14.19.3. Levemir 14.19.4. NovoRapid/ NovoLog 14.19.5. Novomix 14.19.6. Humalog 14.19.7. Others 14.20. GermanyHuman Insulin Market Forecast, By Drug Delivery Devices 14.20.1. Pens 14.20.2. Pen Needles 14.20.3. Syringes 14.20.4. Pumps 14.21. U.K. Human Insulin Market Forecast, By Application 14.21.1. Diabetes Type 1 14.21.2. Diabetes Type 2 14.22. U.K. Human Insulin Market Forecast, By Type 14.22.1. Analogue Insulin 14.22.1.1. Long-Acting 14.22.1.2. Fast-Acting 14.22.1.3. Premix 14.22.2. Traditional human Insulin 14.22.2.1. Long-Acting 14.22.2.2. Short-Acting 14.22.2.3. Fast-Acting 14.22.2.4. Premix 14.23. U.K. Human Insulin Market Forecast, By Distribution Channel 14.23.1. Retail Pharmacies 14.23.2. Hospital Pharmacies 14.23.3. Online Pharmacies 14.24. U.K. Human Insulin Market Forecast, By brand 14.24.1. Lantus 14.24.2. Apidra 14.24.3. Levemir 14.24.4. NovoRapid/ NovoLog 14.24.5. Novomix 14.24.6. Humalog 14.24.7. Others 14.25. U.K. Human Insulin Market Forecast, By Drug Delivery Devices 14.25.1. Pens 14.25.2. Pen Needles 14.25.3. Syringes 14.25.4. Pumps 14.26. France Human Insulin Market Forecast, By Application 14.26.1. Diabetes Type 1 14.26.2. Diabetes Type 2 14.27. France Human Insulin Market Forecast, By Type 14.27.1. Analogue Insulin 14.27.1.1. Long-Acting 14.27.1.2. Fast-Acting 14.27.1.3. Premix 14.27.2. Traditional human Insulin 14.27.2.1. Long-Acting 14.27.2.2. Short-Acting 14.27.2.3. Fast-Acting 14.27.2.4. Premix 14.28. France Human Insulin Market Forecast, By Distribution Channel 14.28.1. Retail Pharmacies 14.28.2. Hospital Pharmacies 14.28.3. Online Pharmacies 14.29. France Human Insulin Market Forecast, By brand 14.29.1. Lantus 14.29.2. Apidra 14.29.3. Levemir 14.29.4. NovoRapid/ NovoLog 14.29.5. Novomix 14.29.6. Humalog 14.29.7. Others 14.30. FranceHuman Insulin Market Forecast, By Drug Delivery Devices 14.30.1. Pens 14.30.2. Pen Needles 14.30.3. Syringes 14.30.4. Pumps 14.31. Italy Human Insulin Market Forecast, By Application 14.31.1. Diabetes Type 1 14.31.2. Diabetes Type 2 14.32. Italy Human Insulin Market Forecast, By Type 14.32.1. Analogue Insulin 14.32.1.1. Long-Acting 14.32.1.2. Fast-Acting 14.32.1.3. Premix 14.32.2. Traditional human Insulin 14.32.2.1. Long-Acting 14.32.2.2. Short-Acting 14.32.2.3. Fast-Acting 14.32.2.4. Premix 14.33. Italy Human Insulin Market Forecast, By Distribution Channel 14.33.1. Retail Pharmacies 14.33.2. Hospital Pharmacies 14.33.3. Online Pharmacies 14.34. Italy Human Insulin Market Forecast, By brand 14.34.1. Lantus 14.34.2. Apidra 14.34.3. Levemir 14.34.4. NovoRapid/ NovoLog 14.34.5. Novomix 14.34.6. Humalog 14.34.7. Others 14.35. Italy Human Insulin Market Forecast, By Drug Delivery Devices 14.35.1. Pens 14.35.2. Pen Needles 14.35.3. Syringes 14.35.4. Pumps 14.36. Spain Human Insulin Market Forecast, By Application 14.36.1. Diabetes Type 1 14.36.2. Diabetes Type 2 14.37. Spain Human Insulin Market Forecast, By Type 14.37.1. Analogue Insulin 14.37.1.1. Long-Acting 14.37.1.2. Fast-Acting 14.37.1.3. Premix 14.37.2. Traditional human Insulin 14.37.2.1. Long-Acting 14.37.2.2. Short-Acting 14.37.2.3. Fast-Acting 14.37.2.4. Premix 14.38. Spain Human Insulin Market Forecast, By Distribution Channel 14.38.1. Retail Pharmacies 14.38.2. Hospital Pharmacies 14.38.3. Online Pharmacies 14.39. Spain Human Insulin Market Forecast, By brand 14.39.1. Lantus 14.39.2. Apidra 14.39.3. Levemir 14.39.4. NovoRapid/ NovoLog 14.39.5. Novomix 14.39.6. Humalog 14.39.7. Others 14.40. Spain Human Insulin Market Forecast, By Drug Delivery Devices 14.40.1. Pens 14.40.2. Pen Needles 14.40.3. Syringes 14.40.4. Pumps 14.41. Rest of Europe Human Insulin Market Forecast, By Application 14.41.1. Diabetes Type 1 14.41.2. Diabetes Type 2 14.42. Rest of Europe Human Insulin Market Forecast, By Type 14.42.1. Analogue Insulin 14.42.1.1. Long-Acting 14.42.1.2. Fast-Acting 14.42.1.3. Premix 14.42.2. Traditional human Insulin 14.42.2.1. Long-Acting 14.42.2.2. Short-Acting 14.42.2.3. Fast-Acting 14.42.2.4. Premix 14.43. Rest Of Europe Human Insulin Market Forecast, By Distribution Channel 14.43.1. Retail Pharmacies 14.43.2. Hospital Pharmacies 14.43.3. Online Pharmacies 14.44. Rest of Europe Human Insulin Market Forecast, By brand 14.44.1. Lantus 14.44.2. Apidra 14.44.3. Levemir 14.44.4. NovoRapid/ NovoLog 14.44.5. Novomix 14.44.6. Humalog 14.44.7. Others 14.45. Rest of Europe. Human Insulin Market Forecast, By Drug Delivery Devices 14.45.1. Pens 14.45.2. Pen Needles 14.45.3. Syringes 14.45.4. Pumps 14.46. Europe Human Insulin Market Attractiveness Analysis 14.46.1. By Application 14.46.2. By Type 14.46.3. By Distribution Channel 14.46.4. By Brand 14.46.5. By Drug Delivery Devices 14.47. PEST Analysis 14.48. Key Trends 14.49. Key Developments 15. Asia Pacific Human Insulin Market Analysis 15.1. Key Findings 15.2. Asia Pacific Human Insulin Market Overview 15.3. Asia Pacific Human Insulin Market Value Share Analysis, By Application 15.4. Asia Pacific Human Insulin Market Forecast, By Application 15.4.1. Diabetes Type 1 15.4.2. Diabetes Type 2 15.5. Asia Pacific Human Insulin Market Value Share Analysis, By Type 15.6. Asia Pacific Human Insulin Market Forecast, By Type 15.6.1. Analogue Insulin 15.6.1.1. Long-Acting 15.6.1.2. Fast-Acting 15.6.1.3. Premix 15.6.2. Traditional human Insulin 15.6.2.1. Long-Acting 15.6.2.2. Short-Acting 15.6.2.3. Fast-Acting 15.6.2.4. Premix 15.7. Asia Pacific Human Insulin Market Value Share Analysis, By Distribution Channel 15.8. Asia Pacific Human Insulin Market Forecast, By Distribution Channel 15.8.1. Retail Pharmacies 15.8.2. Hospital Pharmacies 15.8.3. Online Pharmacies 15.9. Asia Pacific Human Insulin Market Value Share Analysis, By brand 15.10. North America Human Insulin Market Forecast, By brand 15.10.1. Lantus 15.10.2. Apidra 15.10.3. Levemir 15.10.4. NovoRapid/ NovoLog 15.10.5. Novomix 15.10.6. Humalog 15.10.7. Others 15.11. Asia Pacific Human Insulin Market Value Share Analysis, By Drug Delivery Devices 15.12. North America Human Insulin Market Forecast, By Drug Delivery Devices 15.12.1. Pens 15.12.2. Pen Needles 15.12.3. Syringes 15.12.4. Pumps 15.13. Asia Pacific Human Insulin Market Value Share Analysis, by Country 15.14. Asia Pacific Human Insulin Market Forecast, by Country 15.14.1. China 15.14.2. India 15.14.3. Japan 15.14.4. ASEAN 15.14.5. Rest of Asia Pacific 15.15. Asia Pacific Human Insulin Market Analysis, by Country 15.16. China Human Insulin Market Forecast, By Application 15.16.1. Diabetes Type 1 15.16.2. Diabetes Type 2 15.17. China Human Insulin Market Forecast, By Type 15.17.1. Analogue Insulin 15.17.1.1. Long-Acting 15.17.1.2. Fast-Acting 15.17.1.3. Premix 15.17.2. Traditional human Insulin 15.17.2.1. Long-Acting 15.17.2.2. Short-Acting 15.17.2.3. Fast-Acting 15.17.2.4. Premix 15.18. China Human Insulin Market Forecast, By Distribution Channel 15.18.1. Retail Pharmacies 15.18.2. Hospital Pharmacies 15.18.3. Online Pharmacies 15.19. China. Human Insulin Market Forecast, By brand 15.19.1. Lantus 15.19.2. Apidra 15.19.3. Levemir 15.19.4. NovoRapid/ NovoLog 15.19.5. Novomix 15.19.6. Humalog 15.19.7. Others 15.20. China Human Insulin Market Forecast, By Drug Delivery Devices 15.20.1. Pens 15.20.2. Pen Needles 15.20.3. Syringes 15.20.4. Pumps 15.21. India Human Insulin Market Forecast, By Application 15.21.1. Diabetes Type 1 15.21.2. Diabetes Type 2 15.22. India Human Insulin Market Forecast, By Type 15.22.1. Analogue Insulin 15.22.1.1. Long-Acting 15.22.1.2. Fast-Acting 15.22.1.3. Premix 15.22.2. Traditional human Insulin 15.22.2.1. Long-Acting 15.22.2.2. Short-Acting 15.22.2.3. Fast-Acting 15.22.2.4. Premix 15.23. India Human Insulin Market Forecast, By Distribution Channel 15.23.1. Retail Pharmacies 15.23.2. Hospital Pharmacies 15.23.3. Online Pharmacies 15.24. India Human Insulin Market Forecast, By brand 15.24.1. Lantus 15.24.2. Apidra 15.24.3. Levemir 15.24.4. NovoRapid/ NovoLog 15.24.5. Novomix 15.24.6. Humalog 15.24.7. Others 15.25. India Human Insulin Market Forecast, By Drug Delivery Devices 15.25.1. Pens 15.25.2. Pen Needles 15.25.3. Syringes 15.25.4. Pumps 15.26. Japan Human Insulin Market Forecast, By Application 15.26.1. Diabetes Type 1 15.26.2. Diabetes Type 2 15.27. Japan Human Insulin Market Forecast, By Type 15.27.1. Analogue Insulin 15.27.1.1. Long-Acting 15.27.1.2. Fast-Acting 15.27.1.3. Premix 15.27.2. Traditional human Insulin 15.27.2.1. Long-Acting 15.27.2.2. Short-Acting 15.27.2.3. Fast-Acting 15.27.2.4. Premix 15.28. Japan Human Insulin Market Forecast, By Distribution Channel 15.28.1. Retail Pharmacies 15.28.2. Hospital Pharmacies 15.28.3. Online Pharmacies 15.29. Japan Human Insulin Market Forecast, By brand 15.29.1. Lantus 15.29.2. Apidra 15.29.3. Levemir 15.29.4. NovoRapid/ NovoLog 15.29.5. Novomix 15.29.6. Humalog 15.29.7. Others 15.30. Japan Human Insulin Market Forecast, By Drug Delivery Devices 15.30.1. Pens 15.30.2. Pen Needles 15.30.3. Syringes 15.30.4. Pumps 15.31. ASEAN Human Insulin Market Forecast, By Application 15.31.1. Diabetes Type 1 15.31.2. Diabetes Type 2 15.32. ASEAN Human Insulin Market Forecast, By Type 15.32.1. Analogue Insulin 15.32.1.1. Long-Acting 15.32.1.2. Fast-Acting 15.32.1.3. Premix 15.32.2. Traditional human Insulin 15.32.2.1. Long-Acting 15.32.2.2. Short-Acting 15.32.2.3. Fast-Acting 15.32.2.4. Premix 15.33. ASEAN Human Insulin Market Forecast, By Distribution Channel 15.33.1. Retail Pharmacies 15.33.2. Hospital Pharmacies 15.33.3. Online Pharmacies 15.34. ASEAN Human Insulin Market Forecast, By brand 15.34.1. Lantus 15.34.2. Apidra 15.34.3. Levemir 15.34.4. NovoRapid/ NovoLog 15.34.5. Novomix 15.34.6. Humalog 15.34.7. Others 15.35. ASEAN Human Insulin Market Forecast, By Drug Delivery Devices 15.35.1. Pens 15.35.2. Pen Needles 15.35.3. Syringes 15.35.4. Pumps 15.36. Rest of Asia Pacific Human Insulin Market Forecast, By Application 15.36.1. Diabetes Type 1 15.36.2. Diabetes Type 2 15.37. Rest of Asia Pacific Human Insulin Market Forecast, By Type 15.37.1. Analogue Insulin 15.37.1.1. Long-Acting 15.37.1.2. Fast-Acting 15.37.1.3. Premix 15.37.2. Traditional human Insulin 15.37.2.1. Long-Acting 15.37.2.2. Short-Acting 15.37.2.3. Fast-Acting 15.37.2.4. Premix 15.38. Rest of Asia Pacific Human Insulin Market Forecast, By Distribution Channel 15.38.1. Retail Pharmacies 15.38.2. Hospital Pharmacies 15.38.3. Online Pharmacies 15.39. Rest of Asia Human Insulin Market Forecast, By brand 15.39.1. Lantus 15.39.2. Apidra 15.39.3. Levemir 15.39.4. NovoRapid/ NovoLog 15.39.5. Novomix 15.39.6. Humalog 15.39.7. Others 15.40. Rest of Asia Human Insulin Market Forecast, By Drug Delivery Devices 15.40.1. Pens 15.40.2. Pen Needles 15.40.3. Syringes 15.40.4. Pumps 15.41. Asia Pacific Human Insulin Market Attractiveness Analysis 15.41.1. By Application 15.41.2. By Type 15.41.3. By Distribution Channel 15.41.4. By Brand 15.41.5. By Drug Delivery Devices 15.42. PEST Analysis 15.43. Key Trends 15.44. Key Developments 16. Middle East & Africa Human Insulin Market Analysis 16.1. Key Findings 16.2. Middle East & Africa Human Insulin Market Overview 16.3. Middle East & Africa Human Insulin Market Value Share Analysis, By Application 16.4. Middle East & Africa Human Insulin Market Forecast, By Application 16.4.1. Diabetes Type 1 16.4.2. Diabetes Type 2 16.5. Middle East & Africa Human Insulin Market Value Share Analysis, By Type 16.6. Middle East & Africa Human Insulin Market Forecast, By Type 16.6.1. Analogue Insulin 16.6.1.1. Long-Acting 16.6.1.2. Fast-Acting 16.6.1.3. Premix 16.6.2. Traditional human Insulin 16.6.2.1. Long-Acting 16.6.2.2. Short-Acting 16.6.2.3. Fast-Acting 16.6.2.4. Premix 16.7. Middle East & Africa Human Insulin Market Value Share Analysis, By Distribution Channel 16.8. Middle East & Africa Human Insulin Market Forecast, By Distribution Channel 16.8.1. Retail Pharmacies 16.8.2. Hospital Pharmacies 16.8.3. Online Pharmacies 16.9. Middle East & Africa Human Insulin Market Value Share Analysis, By brand 16.10. North America Human Insulin Market Forecast, By brand 16.10.1. Lantus 16.10.2. Apidra 16.10.3. Levemir 16.10.4. NovoRapid/ NovoLog 16.10.5. Novomix 16.10.6. Humalog 16.10.7. Others 16.11. Middle East & Africa North America Human Insulin Market Value Share Analysis, By Drug Delivery Devices 16.12. North America Human Insulin Market Forecast, By Drug Delivery Devices 16.12.1. Pens 16.12.2. Pen Needles 16.12.3. Syringes 16.12.4. Pumps 16.13. Middle East & Africa Human Insulin Market Value Share Analysis, by Country 16.14. Middle East & Africa Human Insulin Market Forecast, by Country 16.14.1. GCC 16.14.2. South Africa 16.14.3. Rest of Middle East & Africa 16.15. Middle East & Africa Human Insulin Market Analysis, by Country 16.16. GCC Human Insulin Market Forecast, By Application 16.16.1. Diabetes Type 1 16.16.2. Diabetes Type 2 16.17. GCC Human Insulin Market Forecast, By Type 16.17.1. Analogue Insulin 16.17.1.1. Long-Acting 16.17.1.2. Fast-Acting 16.17.1.3. Premix 16.17.2. Traditional human Insulin 16.17.2.1. Long-Acting 16.17.2.2. Short-Acting 16.17.2.3. Fast-Acting 16.17.2.4. Premix 16.18. GCC Human Insulin Market Forecast, By Distribution Channel 16.18.1. Retail Pharmacies 16.18.2. Hospital Pharmacies 16.18.3. Online Pharmacies 16.19. GCC U.S. Human Insulin Market Forecast, By brand 16.19.1. Lantus 16.19.2. Apidra 16.19.3. Levemir 16.19.4. NovoRapid/ NovoLog 16.19.5. Novomix 16.19.6. Humalog 16.19.7. Others 16.20. GCC Human Insulin Market Forecast, By Drug Delivery Devices 16.20.1. Pens 16.20.2. Pen Needles 16.20.3. Syringes 16.20.4. Pumps 16.21. South Africa Human Insulin Market Forecast, By Application 16.21.1. Diabetes Type 1 16.21.2. Diabetes Type 2 16.22. South Africa Human Insulin Market Forecast, By Type 16.22.1. Analogue Insulin 16.22.1.1. Long-Acting 16.22.1.2. Fast-Acting 16.22.1.3. Premix 16.22.2. Traditional human Insulin 16.22.2.1. Long-Acting 16.22.2.2. Short-Acting 16.22.2.3. Fast-Acting 16.22.2.4. Premix 16.23. South Africa Human Insulin Market Forecast, By Distribution Channel 16.23.1. Retail Pharmacies 16.23.2. Hospital Pharmacies 16.23.3. Online Pharmacies 16.24. South Africa Human Insulin Market Forecast, By brand 16.24.1. Lantus 16.24.2. Apidra 16.24.3. Levemir 16.24.4. NovoRapid/ NovoLog 16.24.5. Novomix 16.24.6. Humalog 16.24.7. Others 16.25. South Africa U.S. Human Insulin Market Forecast, By Drug Delivery Devices 16.25.1. Pens 16.25.2. Pen Needles 16.25.3. Syringes 16.25.4. Pumps 16.26. Rest of Middle East & Africa Human Insulin Market Forecast, By Application 16.26.1. Diabetes Type 1 16.26.2. Diabetes Type 2 16.27. Rest of Middle East & Africa Human Insulin Market Forecast, By Type 16.27.1. Analogue Insulin 16.27.1.1. Long-Acting 16.27.1.2. Fast-Acting 16.27.1.3. Premix 16.27.2. Traditional human Insulin 16.27.2.1. Long-Acting 16.27.2.2. Short-Acting 16.27.2.3. Fast-Acting 16.27.2.4. Premix 16.28. Middle East & Africa Human Insulin Market Forecast, By Distribution Channel 16.28.1. Retail Pharmacies 16.28.2. Hospital Pharmacies 16.28.3. Online Pharmacies 16.29. Rest of Middle East & Africa Human Insulin Market Forecast, By brand 16.29.1. Lantus 16.29.2. Apidra 16.29.3. Levemir 16.29.4. NovoRapid/ NovoLog 16.29.5. Novomix 16.29.6. Humalog 16.29.7. Others 16.30. Rest of Middle East & Africa Human Insulin Market Forecast, By Drug Delivery Devices 16.30.1. Pens 16.30.2. Pen Needles 16.30.3. Syringes 16.30.4. Pumps 16.31. Middle East & Africa Human Insulin Market Attractiveness Analysis 16.31.1. By Application 16.31.2. By Type 16.31.3. By Distribution Channel 16.31.4. By Brand 16.31.5. By Drug Delivery Devices 16.32. PEST Analysis 16.33. Key Trends 16.34. Key Developments 17. South America Human Insulin Market Analysis 17.1. Key Findings 17.2. South America Human Insulin Market Overview 17.3. South America Human Insulin Market Value Share Analysis, By Application 17.4. South America Human Insulin Market Forecast, By Application 17.4.1. Diabetes Type 1 17.4.2. Diabetes Type 2 17.5. South America Human Insulin Market Value Share Analysis, By Type 17.6. South America Human Insulin Market Forecast, By Type 17.6.1. Analogue Insulin 17.6.1.1. Long-Acting 17.6.1.2. Fast-Acting 17.6.1.3. Premix 17.6.2. Traditional human Insulin 17.6.2.1. Long-Acting 17.6.2.2. Short-Acting 17.6.2.3. Fast-Acting 17.6.2.4. Premix 17.7. South America Human Insulin Market Value Share Analysis, By Distribution Channel 17.8. South America Human Insulin Market Forecast, By Distribution Channel 17.8.1. Retail Pharmacies 17.8.2. Hospital Pharmacies 17.8.3. Online Pharmacies 17.9. South America Human Insulin Market Value Share Analysis, By brand 17.10. South America Human Insulin Market Forecast, By brand 17.10.1. Lantus 17.10.2. Apidra 17.10.3. Levemir 17.10.4. NovoRapid/ NovoLog 17.10.5. Novomix 17.10.6. Humalog 17.10.7. Others 17.11. South America Human Insulin Market Value Share Analysis, By Drug Delivery Devices 17.12. South America Human Insulin Market Forecast, By Drug Delivery Devices 17.12.1. Pens 17.12.2. Pen Needles 17.12.3. Syringes 17.12.4. Pumps 17.13. South America Human Insulin Market Value Share Analysis, by Country 17.14. South America Human Insulin Market Forecast, by Country 17.14.1. Brazil 17.14.2. Mexico 17.14.3. Rest of South America 17.15. South America Human Insulin Market Analysis, by Country 17.16. Brazil Human Insulin Market Forecast, By Application 17.16.1. Diabetes Type 1 17.16.2. Diabetes Type 2 17.17. Brazil Human Insulin Market Forecast, By Type 17.17.1. Analogue Insulin 17.17.1.1. Long-Acting 17.17.1.2. Fast-Acting 17.17.1.3. Premix 17.17.2. Traditional human Insulin 17.17.2.1. Long-Acting 17.17.2.2. Short-Acting 17.17.2.3. Fast-Acting 17.17.2.4. Premix 17.18. Brazil Human Insulin Market Forecast, By Distribution Channel 17.18.1. Retail Pharmacies 17.18.2. Hospital Pharmacies 17.18.3. Online Pharmacies 17.19. Brazil Human Insulin Market Forecast, By brand 17.19.1. Lantus 17.19.2. Apidra 17.19.3. Levemir 17.19.4. NovoRapid/ NovoLog 17.19.5. Novomix 17.19.6. Humalog 17.19.7. Others 17.20. Brazil. Human Insulin Market Forecast, By Drug Delivery Devices 17.20.1. Pens 17.20.2. Pen Needles 17.20.3. Syringes 17.20.4. Pumps 17.21. Mexico Human Insulin Market Forecast, By Application 17.21.1. Diabetes Type 1 17.21.2. Diabetes Type 2 17.22. Mexico Human Insulin Market Forecast, By Type 17.22.1. Analogue Insulin 17.22.1.1. Long-Acting 17.22.1.2. Fast-Acting 17.22.1.3. Premix 17.22.2. Traditional human Insulin 17.22.2.1. Long-Acting 17.22.2.2. Short-Acting 17.22.2.3. Fast-Acting 17.22.2.4. Premix 17.23. Mexico Human Insulin Market Forecast, By Distribution Channel 17.23.1. Retail Pharmacies 17.23.2. Hospital Pharmacies 17.23.3. Online Pharmacies 17.24. Mexico Human Insulin Market Forecast, By brand 17.24.1. Lantus 17.24.2. Apidra 17.24.3. Levemir 17.24.4. NovoRapid/ NovoLog 17.24.5. Novomix 17.24.6. Humalog 17.24.7. Others 17.25. Mexico Human Insulin Market Forecast, By Drug Delivery Devices 17.25.1. Pens 17.25.2. Pen Needles 17.25.3. Syringes 17.25.4. Pumps 17.26. Rest of South America Human Insulin Market Forecast, By Application 17.26.1. Diabetes Type 1 17.26.2. Diabetes Type 2 17.27. Rest of South America Human Insulin Market Forecast, By Type 17.27.1. Analogue Insulin 17.27.1.1. Long-Acting 17.27.1.2. Fast-Acting 17.27.1.3. Premix 17.27.2. Traditional human Insulin 17.27.2.1. Long-Acting 17.27.2.2. Short-Acting 17.27.2.3. Fast-Acting 17.27.2.4. Premix 17.28. Rest of South America Human Insulin Market Forecast, By Distribution Channel 17.28.1. Retail Pharmacies 17.28.2. Hospital Pharmacies 17.28.3. Online Pharmacies 17.29. Rest of South America Human Insulin Market Forecast, By brand 17.29.1. Lantus 17.29.2. Apidra 17.29.3. Levemir 17.29.4. NovoRapid/ NovoLog 17.29.5. Novomix 17.29.6. Humalog 17.29.7. Others 17.30. Rest of South America Human Insulin Market Forecast, By Drug Delivery Devices 17.30.1. Pens 17.30.2. Pen Needles 17.30.3. Syringes 17.30.4. Pumps 17.31. South America Human Insulin Market Attractiveness Analysis 17.31.1. By Application 17.31.2. By Type 17.31.3. By Distribution Channel 17.31.4. By Brand 17.31.5. By Drug Delivery Devices 17.32. PEST Analysis 17.33. Key Trends 17.34. Key Developments 18. Company Profiles 18.1. Market Share Analysis, by Company 18.2. Competition Matrix 18.2.1. Competitive Benchmarking of key players by price, presence, market share, Applications and R&D investment 18.2.2. New Product Launches and Product Enhancements 18.2.3. Market Consolidation 18.2.3.1. M&A by Regions, Investment and Applications 18.2.3.2. M&A Key Players, Forward Integration and Backward 18.2.3.3. Integration 18.3. Company Profiles: Key Players 18.3.1. B. Braun Melsungen AG 18.3.1.1. Company Overview 18.3.1.2. Financial Overview 18.3.1.3. Product Portfolio 18.3.1.4. Business Strategy 18.3.1.5. Recent Developments 18.3.1.6. Development Footprint 18.3.2. ALBIREO PHARMA, INC 18.3.3. BECTON, DICKINSON AND COMPANY 18.3.4. BIOCON LIMITED 18.3.5. Sanofi Aventis 18.3.6. WOCKHARDT LIMITED 18.3.7. JULPHAR 18.3.8. YPSOMED HOLDING AG 18.3.9. ELI LILLY AND COMPANY 18.3.10. NOVO Nordisk A/S 18.3.11. ADOCIA 18.3.12. Tonghua Dongbao Pharmaceutical Co., LTD 18.3.13. GSK 18.3.14. Gulf Pharmaceutical Industries 18.3.15. Medtronic PLC 18.3.16. Oramed Pharmaceuticals, Inc 18.3.17. SemBioSys Genetics 18.3.18. Pfizer, Inc. 18.3.19. Merck & Co., Inc. 19. Primary Key Insights

About This Report

Report ID54257
Category Healthcare
Published DateMarch 2020
No of Pages307
Contact Us
Call Now